Mage-a3

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 17.06.2022

Dieser Artikel auf Deutsch

Synonym(s)

Melanoma-associated antigen 3

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Protein that in humans is encoded by the MAGE-A3 gene. The MAGE-A3 gene (MAGE stands for "melanoma associated antigen gene") is a member of the "melanoma-associated antigen gene family" (MAGE superfamily) located on chromosome Xq28. The MAGE gene group has been implicated in dyskeratosis congenita.

The MAGE-A3 protein is a tumor-specific protein that has been identified in a number of malignancies, including malignant melanoma (see names), non-small cell lung carcinoma, adenocarcinomas and various lymphomas. lymphomas.

The MAGE-A3 protein is not detected in normal body cells. Its detection on tumor cells has been associated with poor prognosis. Thus, high levels of MAGE-A3 in adenocarcinomas of the lung are associated with shorter survival.

Note(s)This section has been translated automatically.

GlaxoSmithKline developed a vaccine (not yet approved) against the MAGE-A3 protein. The vaccine is a fusion protein of MAGE-A3 and the Haemophilus influenzae protein D, combined with an immunoadjuvant. First study results were already presented in 2007. A randomized Phase II study examined MAGE-A3-ASCI in combination with two different adjuvant systems in a total of 72 patients with metastatic MAGE-A3-positive malignant melanoma of the skin. The patients received immunotherapy either in combination with the adjuvant AS15 or with AS02B as first-line treatment. A complete or partial response was observed in 4 patients in the AS15 group. Without adjuvant 1 patient showed a short-term partial response. The adverse events were mild or moderate local or systemic responses. Further study results are awaited.

LiteratureThis section has been translated automatically.

  1. Olarte I et al (2011) MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Hematology 16:368-372
  2. Park JH et al (2012) Usefulness of the melanoma antigen gene (MAGE) in making the differential diagnosis between pleomorphic adenoma and adenoid cystic carcinoma. J Otolaryngol Head Neck Surg 41:20-29
  3. van der Bruggen P et al (1992) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma". Science 254: 1643-1647
  4. Russo V et al.l (2011) A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer 2:329-330
  5. Kähler KC et al (2011) Adjuvant systemic treatment of melanoma. Dermatologist 62: 416-22

Authors

Last updated on: 17.06.2022

Author: Prof. Dr. med. Peter Altmeyer